Timely and actionable news, comments, and investment opinions on biotechnology
companies, including buy and sell decisions, which are centered on the InvestBio
Model Portfolio. The Alerts are sent via email to members for quick and
knowledgeable investment decisions as the market reacts to the news.InvestBio
PRO is produced by an experienced team of industry leaders. The highly
accredited Scientific Advisory Board, which is headed by Dr. Ron Garren, Chief
Biotechnology Strategist, collectively possesses decades of experience and
expertise, thus offering the best perspective to individuals interested in
investing in biotech companies. Other sources do not have the experience, the
team or the real insight and knowledge; only InvestBio PRO is designed to help
individual investors become wealthy through investing in biotechnology.
Dr. Ron Garren — InvestBio's Chief Biotechnology Strategist
Ronald Garren, a Harvard Medical School graduate and board certified internist,
has been practicing medicine for 30 years. Garren’s clinical expertise is in the
field of oncology, and his remarkable career has included a residency at New
York Hospital and a three-year postdoctoral fellowship in molecular biology at
Stanford in Dr. Paul Berg's lab. It is this unique combination of experiences
that makes Garren’s evaluation of the biotech field so compelling. His
experience and expertise enables him to present a valuable perspective to
individuals interested in investing in biotech.
A biotechnology revolution is taking place right now. Amazing breakthroughs like
the mapping of the human genome will have an unprecedented impact on our ability
to cure deadly diseases and prolong lives. The advances in our quality of life
will be extraordinary.
For biotech investors, the opportunities have never been greater. Biotechnology
is now positioned as one of the most promising sectors on Wall Street, and
the profit potential is enormous.